Oncology & Cancer

Helene Lindfors, Ph.D. Student at the Endocrine Surgery research group, the Department of Molecular Medicine and Surgery, will defend her thesis “Tumor burden, thyroglobulin and Ki-67 as prognostic indicators in papillary thyroid cancer” on April 11, 2025. The main supervisor is Ivan Shabo.

As more people receive genetic testing after a cancer diagnosis, newer variants have been identified that increase the risk of developing cancer. A recent study led by the University of Michigan Rogel Cancer Center finds that patients with three of these variants face no extra risk of dying from their cancer.

One of the most common side effects of cancer treatments, including chemotherapy and radiation therapy, is fatigue. Cancer-related fatigue is often worse and harder to manage compared to the fatigue in people without cancer and can sometimes persist weeks, months or even years after treatment ends.

A groundbreaking study has revealed a significant link between the frequency of chest X-ray referrals from GPs and earlier diagnosis and improved survival rates for lung cancer patients.

Patients with certain subtypes of breast cancer may face a higher risk of death from the cancer if they wait more than 42 days after diagnosis to have surgery, according to newly published research from the University of Oklahoma.

Among other functions, the NK cells (natural killers, a type of lymphocyte forming part of the immune system) have the capacity to detect and eliminate cancer cells. But in some cases they cannot overcome the tumor’s defense mechanism and the cancer grows.

B-cell acute lymphoblastic leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most common childhood cancer, making up 35% of pediatric cancer cases, but it can affect people of any age. CAR T-cell therapy has significantly improved outcomes for B-ALL patients, but relapse still occurs in over 50% of cases, leaving many with limited treatment options. Ongoing research aims to address this challenge and improve CAR T therapy’s effectiveness.

Scientists at the UCLA Health Jonsson Comprehensive Cancer Center and the University of Toronto have revealed how a tiny chemical modification in RNA, known as m6A, plays a critical role in the progression of prostate cancer, including driving some of its most dangerous forms of the disease.

A team of researchers from Cleveland Clinic Genomic Medicine share insights from an early set of 19,000 patients to receive immune checkpoint inhibitor treatments for colorectal cancer in the U.S.

Since 2021, when lung cancer screening guidelines began to include younger people and those with a lower smoking history, the number of screenings climbed, but significant gaps remain, especially among people with limited access to health care, according to a new study led by researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.